Graft-versus-lymphoma effect in progressive hepatosplenic gamma/delta T-cell lymphoma

Simon Z. He,A. Roberts,D. Ritchie,A. Grigg

DOI: https://doi.org/10.1080/10428190701400071

2007-01-01

Abstract:Hepatosplenic gamma/delta T-cell lymphoma (HSTCL) is a rare clinicopathologic entity with distinctive characteristics including young male predominance, splenomegaly, thrombocytopenia, and bone marrow infiltration [1]. HSTCL has been recognised as a complication of long-term immunosuppressive therapy in solid organ transplantation and for inflammatory bowel disease [2,3]. The outcome is poor due to a complete remission (CR) rate less than 50% and a high rate of early relapse resulting in a median survival of 16 months [1]. Salvage therapeutic options for progressive or relapsed disease are few. 20-deoxycoformycin has been shown to have specific activity against g/d T-cell lymphoma both in vivo and in vitro [4,5]. Alemtuzumab has been reported as effective as salvage therapy [6]. Prolonged disease survival has been reported following allogeneic transplantation [7], but it is not clear whether this represents the effect of myeloablative conditioning or a specific graftversus-HSTCL effect. The following case demonstrates an unequivocal graft-versus-HSTCL effect with medium-term follow-up, suggesting that this disease is susceptible to immunologically mediated cytotoxicity. A 39-year-old Caucasian man on long-term immunosuppression for Crohn’s disease presented in January 2006 with fever, hepatosplenomegaly, pancytopenia, and Staphylococcal sepsis. Liver and bone marrow biopsies revealed prominent atypical lymphoid infiltrate in sinusoids with an immunophenotype (CD2þ, CD3þ, CD47, CD57, and CD87) and T-cell receptor g chain gene rearrangement consistent with HSTCL. Positron emission tomography (PET) confirmed splenic involvement. One cycle of hyperCVAD [8] complicated by severe Pseudomonas sepsis produced a partial response with subsequent rapidly progressive disease. Salvage chemotherapy with one cycle of ifosfamide, carboplatin, and etoposide achieved only a transient response. In June 2006, he underwent a peripheral stem cell allograft from his HLA-matched brother, after conditioning with etoposide (60 mg/kg) and total body irradiation (1320 cGy). At the time of transplant, circulating lymphoma cells were observed in the peripheral blood film with an elevated serum lactate dehydrogenase (LDH) of 2839 IU/l (reference range 210 – 420 IU/l). He developed grade IV mucositis, severe respiratory distress requiring invasive ventilatory support, and acute oliguric renal failure. Granulocyte engraftment occurred on Day 16 with G-CSF support. A restaging bone marrow biopsy on Day 31 revealed approximately 10 – 15% persistent disease involvement (Figure 1), and he developed worsening lethargy, pancytopenia, progressive splenomegaly, and a rapidly increasing LDH to 5977 IU/l. His immunosuppressive regimen consisting of cyclosporin and prednisolone was rapidly weaned and discontinued by Day 35. Cutaneous graft-versus-host disease (GVHD) appeared on Day 40. The onset of GVHD was temporally associated with a progressive fall in LDH (Figure 2). A computerized tomography scan on Day 59 demonstrated resolution of splenomegaly. A Day-59 bone marrow